India's Gland Pharma sees best day in 2 months on US FDA approval for cancer drug

Gland Pharma

08/04/2024 07:14

** Shares of Gland Pharma  GLAD.NS  rise as much as 6.3% to
1,865 rupees, marking sharpest intraday pct gain since Feb. 6
    ** GLAD eyes busiest day in 16 sessions
    ** GLAD received U.S. FDA approval on Saturday for Eribulin
Mesylate Injection, a cancer treatment drug 
    ** Analysts' average rating on the stock is "buy"; median PT
is 1,770 rupees, a discount of ~5.1% to the day's high  - LSEG
data
    ** GLAD top gainer on Nifty Pharma index  .NIPHARM  
    ** As of last close, stock down ~8.8% YTD vs a 13.8% climb
in the pharma index YTD


 (Reporting by Anisha Ajith in Bengaluru)
 ((anisha.ajith@thomsonreuters.com))